Goro Healthcare partners with Demophorius in the UAE and Qatar
Goro Healthcare partners with Demophorius in the UAE and Qatar
Goro Healthcare is proud to announce our partnership with Dmophorius to commercialize and distribute its high quality medical devices in the UAE and Qatar
Demophorius Healthcare is a world leader and global provider of medical devices dedicated
Goro Healthcare launches Neopausil® in the United Arab Emirates
Goro Healthcare is proud to introduce our latest innovation to treat Menopause and Perimenopause symptoms. Neopausil® is a combination of natural ingredients (Resveratrol, Vitamin D and Vitamin E), proven to reduce menopause symptoms by 4 times, and is effective as a hormone replacement therapy (HRT). Neopausil is made in Italy by Pro-Biopharma and
Tanyx® obtain MOHAP registration approval
Tanyx® - a new concept in pain management - has been granted a registration approval for the Ministry of Health And Prevention in the United Arab Emirates. TANYX® is the world’s first US-FDA approved, self applicable and portable TENS (Transcutaneous Electrical Nerve Stimulation) technology based PAIN RELIEF device with patents in 40+ countries. It’s smaller
Goro Healthcare signs an exclusive distribution agreement with The OTClab and Perfect Care Phamra
Goro Healthcare have signed an exclusive distribution agreement with The OTClab and Perfect Care Phamra. The company strengthen its current portfolio with the addition of Bitener, Detoxner IBS, and Cerveron to treat various conditions such as nail biting, Irritable Bowel Syndrom, and Vaginal infections, respectively. The OTClab is A fast-growing global healthcare company
Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response
Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
FDA announces first of its kind program to communicate patient reported outcomes from oncology clinical trials
The U.S. Food and Drug Administration launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer trials for marketed treatments. While this patient-reported data has historically been analyzed by the FDA
Recent News